Structural, functional & molecular neuroimaging biomarkers for AD

November 18, 2023
< 1 mins

Category: Published research

Neuroimaging biomarkers are now routinely incorporated into AD clinical trials and are increasingly used in clinical practice. This paper broadly describes the development and use of these biomarkers as they relate to AD.

[button]Download[/button]

Topic: Published research

More Resources

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

Cortechs.ai news, Industry news, Product updates

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

Cortechs.ai news, Industry news, Product updates

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

Product updates

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

Blogs, Product updates

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.

Blogs

02/11/2026

NeuroQuant Normative Database: Advancing Age‑ and Sex‑Specific Brain Volumetry

Learn how the latest updates to the NeuroQuant normative database white paper strengthen age- and sex-specific brain volumetry and enhance clinical confidence.

Our solutions

Our solutions

About

Support

Resources